We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $15.59, moving -4.24% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.57% for the day. Elsewhere, the Dow lost 1.34%, while the tech-heavy Nasdaq lost 2.04%.
The infectious disease drug developer's shares have seen a decrease of 10.94% over the last month, not keeping up with the Medical sector's loss of 0.8% and the S&P 500's loss of 0.29%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.66% increase. Adma Biologics is holding a Zacks Rank of #2 (Buy) right now.
With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 19.15. This signifies a discount in comparison to the average Forward P/E of 19.61 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $15.59, moving -4.24% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.57% for the day. Elsewhere, the Dow lost 1.34%, while the tech-heavy Nasdaq lost 2.04%.
The infectious disease drug developer's shares have seen a decrease of 10.94% over the last month, not keeping up with the Medical sector's loss of 0.8% and the S&P 500's loss of 0.29%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.66% increase. Adma Biologics is holding a Zacks Rank of #2 (Buy) right now.
With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 19.15. This signifies a discount in comparison to the average Forward P/E of 19.61 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.